Please login to read the full text of the article.
If you have no account yet, please register now.
Posted on
Previous Article
« Tumor marker of bone metastasis in ER+ breast cancer identified Next Article
Pembrolizumab plus bevacizumab and oral cyclophosphamide beneficial in recurrent ovarian cancer »
« Tumor marker of bone metastasis in ER+ breast cancer identified Next Article
Pembrolizumab plus bevacizumab and oral cyclophosphamide beneficial in recurrent ovarian cancer »
Related Articles

July 30, 2019
Interview with Prof. Natalia Rost
© 2021 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy